NA-831 is under clinical development by Biomed Industries and currently in Phase I for Major Depressive Disorder. According to GlobalData, Phase I drugs for Major Depressive Disorder have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NA-831’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NA-831 (traneurocin) is under development for the treatment of Alzheimer’s disease, Coronavirus Disease 2019 (COVID-19), major depressive disorder (MDD), rett syndrome, fragile x syndrome and mild cognitive impairment. The drug candidate is administered orally formulated as capsules and inhalation formulation as nanoparticle. It was also under development for multiple sclerosis and stroke. It was administered intravenously and was delivered using MICROS controlled release infusion system.
Biomed Industries overview
Biomed Industries (Biomed) is a biotechnology company that offers alzheimers research, biotechnology, and medical research services. The company is headquartered in San Jose, California, the US.
For a complete picture of NA-831’s drug-specific PTSR and LoA scores, buy the report here.